Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies

Justin Taylor, … , Jae H. Park, Omar Abdel-Wahab


Graphical abstract

Find the latest version:

http://jci.me/120787/pdf
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies

Justin Taylor,1,2 Dean Pavlick,3 Akishide Yoshimi,1 Christina Marcelus,1 Stephen S. Chung,2 Jaclyn F. Hechtman,4 Ryma Benayed,4 Emiliano Cocco,1 Benjamin H. Durham,1 Lillian Bitner,1 Daichi Inoue,1 Young Rock Chung,2 Kerry Mullaney,4 Justin M. Watts,5 Eli L. Diamond,4 Lee A. Albacker,3 Tariq I. Mughal,3,7 Kevin Ebata,8 Brian B. Tuch,8 Nora Ku,8 Maurizio Scaltriti,1 Mikhail Roshal,4 Maria Arcila,4 Siraj Ali,3 David M. Hyman,9 Jae H. Park,2 and Omar Abdel-Wahab1,2

California, USA. 9Developmental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 6Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 7Tufts University Medical Center, Boston, Massachusetts, USA. 8Loxo Oncology Inc., South San Francisco, California, USA. 1Human Oncology and Pathogenesis Program and 2Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3Foundation Medicine Inc., Cambridge, Massachusetts, USA. 5Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA. 1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2Tufts University Medical Center, Boston, Massachusetts, USA. 4Loxo Oncology Inc., South San Francisco, California, USA. 6Developmental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Introduction

Fusions involving neurotrophic receptor tyrosine kinases (NTRKs) were among the first gene translocations described in cancer (1, 2). NTRK1, NTRK2, and NTRK3 (encoding TrkA, TrkB, and TrkC, respectively; hereafter collectively referred to as TRK) are primarily expressed in neuronal tissue. Rearrangements resulting in fusion of the carboxy-terminal kinase domain of TRK and various upstream amino-terminal partners create chimeric proteins with ectopic expression and constitutive kinase activation. TRK fusions are pathognomonic for several rare solid tumor malignancies (3–6) but are present in fewer than 1% of all solid tumors (7–10). Although TRK fusions are uncommon, efficacy of TRK inhibition in patients with solid tumors harboring these fusions is striking, with an 80% overall response rate for the highly selective pan-TRK inhibitor larotrectinib in a cohort of 17 tumor types (11). Based on these data, larotrectinib received the first tissue-agnostic Breakthrough Therapy designation from the FDA for adult and pediatric patients with advanced solid tumors bearing TRK fusions.

Despite the promise of TRK inhibition in solid tumors, the frequency and characteristics of TRK fusions in hematologic malignancies have not been systematically evaluated nor is there knowledge of the clinical efficacy of TRK inhibition in any hematologic malignancy. Given that individual patients with TRK fusions have been described in acute myeloid leukemia (AML) (12–14), Philadelphia chromosome–like B cell acute lymphoblastic leukemia (Ph-like B-ALL) (15), and histiocytosis (16), TRK fusions may have clinical importance in hematologic malignancies. Here we describe the frequency and characteristics of NTRK1, -2, or -3 fusions across more than 7,000 pediatric and adult patients with hematologic malignancies and report the efficacy of TRK inhibition in a refractory AML patient with an ETV6-NTRK2 fusion.

Results and Discussion

We performed next-generation targeted DNA and RNA sequencing across 7,311 patients with a variety of hematologic malignancies and discovered 8 patients (0.1%) harboring in-frame NTRK1, -2, or -3 fusions that included the full tyrosine kinase domain (Figure 1A and Table 1). TRK fusions occurred equally in males and females and across an age range of younger than 1 to 77 years (Table 1). The denominator (7,311 patients) and demographics for each disease subtype sequenced are listed in Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI120787DS1. Fusions occurred in patients with histiocytic (LMNA-NTRK1, TFG-NTRK1) and dendritic cell (TPR-NTRK1) neoplasms (n = 3/78; 3.8%) as well as ALL (ETV6-NTRK3; n = 1/659; 0.15%) and AML (ETV6-NTRK2, ETV6-NTRK3; n = 2/1201; 0.17%). In addition, we detected 2 multiple myeloma...
patients with NTRK3 fusions (UBE2R2-NTRK3 and HNRNPA2B1-NTRK3; n = 2/1859; 0.11%).

Four of the 8 TRK fusions identified here were either previously unreported in the literature or had been reported but not functionally evaluated. To investigate the functional relevance of these alterations, these 4 fusions were cloned and expressed in c-Kit+ mouse bone marrow (BM) cells where they resulted in a 1.7- to 2.2-fold expansion in colony formation (Figure 1B) and increased activation of AKT and PLCγ1 (Figure 1C). Despite uniform growth-promoting properties in primary murine BM cells and equivalent levels of TRK protein expression, each TRK fusion displayed distinct transforming and transphosphorylation properties in murine 32D and Ba/F3 hematopoietic cell lines. For example, LMNA-NTRK1, ETV6-NTRK2, and UBE2R2-NTRK3 fusions caused robust cytokine-independent growth of both Ba/F3 and 32D cells, whereas the HNRP2B1I-NTRK3 fusion did not transform Ba/F3 cells (Figure 1D and Supplemental Figure 1A). Consistent with these different growth properties, each fusion activated or did not activate PI3K-AKT, MAPK, and PLCγ1 signaling to differing degrees (Supplemental Figure 1B). Regardless of potential differences in lineage-dependent transforming capacities, expression of TRK fusions in primary mouse BM or cell lines conferred sensitivity to TRK inhibition (Figure 2, A and B and Supplemental Figure 1C).

The above studies identified a 77-year-old man with a history of chronic lymphocytic leukemia (CLL) who had developed refractory secondary AML with ETV6-NTRK2 as well as ETV6-MECOM fusions plus 7 additional mutations (Table 1). Quantitative reverse-transcriptase PCR (qRT-PCR) analysis of FACS-purified CLL and AML populations identified that the ETV6-NTRK2 fusion plus 7 additional mutations (Table 1). Quantitative reverse-transcriptase PCR (qRT-PCR) analysis of FACS-purified CLL and AML populations identified that the ETV6-NTRK2 fusion was restricted to AML and not expressed in residual CLL (Supplemental Figure 2, A and B). A patient-derived xenograft (PDX) was generated and tested for potential sensitivity to larotrectinib. The schema for creating the PDX is diagrammed in Figure 2C. Once engraftment of human myeloid cells was greater than 10% of total, live BM mononuclear cells (MNCs), engrafted mice were randomized to receive oral larotrectinib (150 mg/kg/day) or vehicle for 14 days (note, there was no evidence of CLL cell engraftment in vivo). Larotrectinib treatment reduced human chimerism as measured by FACS and histologic analysis (Figure 2D and Supplemental Figure 2C; discrepancy in human CD45 percentages between FACS and histology are due to sample in entire skeleton versus one bone, respectively). Consistent with this response, ETV6-NTRK2 expression was dramatically reduced in larotrectinib-treated mice (Supplemental Figure 2D) with the residual remaining cells positive only for the co-occurring ETV6-MECOM fusion.

Given the response in the PDX and lack of treatment options, the above-mentioned patient received 100 mg larotrectinib twice daily (provided under FDA expanded access) and attained a partial response (17) as assessed by BM biopsy at day 60 (BM blasts decreased from 54% to 20% with absolute neutrophil count >1,000/μL and platelet count >100,000/μL). A greater than 50% reduction in peripheral blood blasts occurred over 10 weeks coincident with a reduction in the abundance of ETV6-NTRK2 fusion transcripts (Figure 3A), and the patient achieved a partial remission (full clinical parameters shown in Supplemental Table 2). A 10-day treatment interruption due to respiratory distress and temporary intubation (unrelated to larotrectinib) resulted in an increase in circulating blast percentage, which was once again reduced when larotrectinib was reinitiated. Overall, the clinical response to larotrectinib was mirrored by changes in the abundance of the ETV6-NTRK2 fusion (Figure 3, A and B).

After 10 to 12 weeks of treatment, the patient eventually showed signs of clinical relapse and opted for supportive care. To

Table 1. NTRK fusions identified across 7,311 patients with hematologic malignancies

<table>
<thead>
<tr>
<th>Disease</th>
<th>Age, y</th>
<th>Sex</th>
<th>Fusion</th>
<th>Breakpoint location</th>
<th>Previously identified</th>
<th>Previously functionally evaluated</th>
<th>Other genetic alterations</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECD</td>
<td>27</td>
<td>M</td>
<td>LMNA-NTRK1</td>
<td>LMNA: intron 5, NTRK1: exon 11</td>
<td>Yes (H/S)</td>
<td>N</td>
<td>None</td>
</tr>
<tr>
<td>ECD</td>
<td>2 mo</td>
<td>M</td>
<td>TFG-NTRK1</td>
<td>TFG: intron 7, NTRK1: intron 11</td>
<td>Yes (S)</td>
<td>Yes</td>
<td>CDKN2A and CDKN2B loss</td>
</tr>
<tr>
<td>IDCS</td>
<td>20</td>
<td>F</td>
<td>TPR-NTRK1</td>
<td>TPR: intron 21, NTRK1: intron 9</td>
<td>Yes (H/S)</td>
<td>Yes</td>
<td>CDKN2A and CDKN2B loss</td>
</tr>
<tr>
<td>MM</td>
<td>53</td>
<td>F</td>
<td>UBE2R2-NTRK3</td>
<td>UBE2R2: intron 3, NTRK3: intron 3</td>
<td>No</td>
<td>No</td>
<td>KRASQ61H, CXCR4S323fs, MTORD2S12Y, TRAF3584*, IGH-WWOX fusion</td>
</tr>
<tr>
<td>MM</td>
<td>76</td>
<td>F</td>
<td>HNRPB2B1-NTRK3</td>
<td>HNRPB2B1: intron 7, NTRK3: intron 13</td>
<td>No</td>
<td>No</td>
<td>None</td>
</tr>
<tr>
<td>B-ALL</td>
<td>11</td>
<td>F</td>
<td>ETV6-NTRK3</td>
<td>ETV6: intron 5, NTRK3: intron 14</td>
<td>Yes (H/S)</td>
<td>Yes</td>
<td>JAK2T875N, PTPN11S530A, WTTW350R, CRLF2P2R88 fusion, CDKN2A and CDKN2B loss</td>
</tr>
<tr>
<td>AML</td>
<td>54</td>
<td>F</td>
<td>ETV6-NTRK3</td>
<td>ETV6: intron 4, NTRK3: intron 14</td>
<td>Yes (H/S)</td>
<td>Yes</td>
<td>IDH1 R132H, CBLQ367R, DMN14888, NPM1N228R, FLT3F596, Y597ins59, HUCE loss</td>
</tr>
<tr>
<td>AML</td>
<td>77</td>
<td>M</td>
<td>ETV6-NTRK2</td>
<td>ETV6: intron 5, NTRK2: intron 15</td>
<td>No</td>
<td>No</td>
<td>CHEX2E457fs, CHEX2R217fs, NF1Q272Y*, DMN13AW698*, ASXL1S66fs, K45S61fs, CDK18 deletion, ET6-MECOM fusion</td>
</tr>
</tbody>
</table>

*Previously reported in a case of either hematologic (H) or solid tumor (S) malignancy. AML, acute myeloid leukemia; B-ALL, B cell acute lymphoblastic leukemia; ECD, Erdheim-Chester disease; IDCS, interdigitating dendritic cell sarcoma; MM, multiple myeloma.
Figure 1. Transforming TRK fusions are present across hematologic malignancies and cause transformation in a cell-type specific manner. (A) Diagram of the TRK fusions identified across 7,311 patients with hematologic malignancy, with the domain of each protein included in the fusion and the nucleotide sequence at the break points shown. The carboxy-terminal kinase domains of TRK proteins are fused in-frame to the amino-terminal fusion partners. (B) Methylcellulose colony numbers formed by murine c-Kit+ bone marrow transduced with the indicated fusion proteins (CFU-GM, colony-forming unit granulocyte-macrophage; CFU-GEMM, colony-forming unit granulocyte, erythrocyte, monocyte, megakaryocyte; and BFU-E, burst-forming unit erythroid). (C) Western blot performed on lysates from cells in B. Blots were stripped and reprobed for total proteins after respective phospho-proteins. (D) Growth of 32D cells in media lacking IL-3 either expressing the indicated fusion protein or transduced with the empty vector (EV) as negative control. Error bars represent mean and SD from triplicate samples. Differences were calculated using a 2-sided Student’s t test and corrected for multiple testing using the Bonferroni method (*P < 0.0125).
Figure 2. TRK fusions confer responsiveness to TRK inhibition in hematopoietic malignancies in vitro and in vivo. (A) Colony numbers derived from c-Kit+ murine bone marrow cells stably expressing the indicated constructs grown in increasing concentrations (0, 25, and 50 nM) of larotrectinib in methylcellulose. (B) Cell viability of IL-3-independent 32D cells expressing TRK fusions following 72 hours of larotrectinib or vehicle treatment. The IC₅₀ is calculated from the slope of the log inhibitor versus response curve. (C) Schematic of creation and testing of larotrectinib in a PDX from a patient with AML with an ETV6-NTRK2 fusion. (D) Flow cytometric analysis of mouse versus human cell subsets (mCD45 versus hCD45) in BM of a PDX after larotrectinib or vehicle treatment. Each row represents a distinct individual mouse xenografted with the same patient sample; all percentages represent percentage of live mouse Ter119-negative (mTer119-negative) cells. (E) Anti-hCD45 immunohistochemical analysis in BM from PDX mice treated with vehicle or larotrectinib for 14 days (top row scale bar, 200 μm; bottom row scale bar, 50 μm). Each column represents a distinct individual mouse xenografted with the same patient sample. Error bars represent mean and SD from triplicate samples. Differences were calculated using a 2-sided Student’s t test and corrected for multiple testing using the Bonferroni method (*P < 0.0125).
evaluate the cause of relapse after larotrectinib therapy, we characterized *ETV6-NTRK2* expression across the immunophenotypically distinct AML subpopulations. This analysis revealed that the *ETV6-NTRK2* fusion was present in only 1 AML subpopulation of leukemic blasts at baseline (Supplemental Figure 2, A and B). Flow cytometric analysis of serial BM obtained during larotrectinib treatment revealed elimination of the population bearing the *ETV6-NTRK2* fusion (CD33+CD34+CD117-CD11B+CD13-CD64+ cells) with continued presence of the population expressing the *ETV6-MECOM* fusion (CD33+CD34+CD117+CD11b-CD123+CD13+CD64- cells) (Figure 3C and Supplemental Figure 2E). Serial targeted RNA sequencing identified reduced *ETV6-NTRK2* expression throughout larotrectinib treatment with concomitant increased *ETV6-MECOM* expression (Figure 3A). No mutations in *NTRK2*, including mutations associated with resistance to TRK inhibition (18), were detected at any time point, suggesting that clinical progression on larotrectinib was due to an expansion of the TRK fusion–negative AML clone, noted to be present at baseline.

We herein describe that TRK fusions occur across patients with a wide variety of hematologic malignancies and are amenable to TRK inhibition. In addition to prior data identifying TRK fusions in patients with AML (12–14), Ph-like B-ALL (15), and histiocytosis (16), we also document TRK fusions in multiple myeloma and dendritic cell neoplasms. Although the frequency of TRK fusions appears to be rare across a very wide spectrum of leukemias and lymphoid malignancies studied here, the antitumor activity of larotrectinib seen here calls for systematic identification of TRK fusions in the clinical evaluation of hematologic malignancy patients with refractory disease. In the solid tumor setting, immunohistochemistry (IHC) with a pan-TRK antibody has shown potential for TRK fusion detection in certain settings (19). However, TRK IHC has not been studied in hematologic malignancies, where expression of TRK kinases in the absence of gene rearrangements has been described (20, 21). As noted earlier, the efficacy of larotrectinib in TRK fusion–expressing cancer types was very recently demonstrated in a histology- and age-agnostic study of children and adults with solid tumors. In this study, 55 patients with 17 TRK fusion–positive tumor types received larotrectinib with an objective response rate of 80% (11). In the solid tumor experience, occasional on-
target mechanisms of acquired drug resistance were observed to occur due to drug-resistant mutations in the kinase domain of TRK proteins. By contrast, in this case of the ETV6-NTRK2-expressing AML patient, the TRK fusion clone was suppressed by TRK inhibition, but ultimately the efficacy of TRK inhibition was limited by the subclonal nature of the fusion. Further efforts to correlate the response to TRK inhibition with the clonal nature of TRK fusion expression will thus be important to determining how durable responses will be in hematologic malignancies. In the setting of subclonal TRK fusions, combination strategies employing highly selective inhibitors with other anticancer agents with limited overlapping toxicities will likely be required to achieve complete responses.

Methods

**Patient samples.** Targeted DNA (>50 ng) and RNA (>300 ng) sequencing was interrogated using the FoundationOne Heme Panel (Foundation Medicine Inc.) (22). The panel analyzes the complete coding DNA sequence of 405 genes, as well as selected introns of 31 genes involved in chromosomal rearrangements. It also interrogates the RNA sequence of 265 genes commonly rearranged into fusions. Although raw sequencing data from the FoundationOne Heme Assay is not available for public accessibility, researchers may contact Foundation Medicine Inc. to discuss or request access (client-services@foundationmedicine.com).

**Anchored multiplex PCR for targeted next-generation sequencing of fusions.** Detailed methods for multiplex fusion PCR are provided in the Supplemental Materials.

**Xenotransplantation.** Six-week-old NSGS (stock 013062) mice were sublethally irradiated (200 cGy) 24 hours before transplantation followed by direct intrafemoral injection (23). Viably frozen BM MNCs were used for xenografts and engrafted into the maximal number of recipient animals (which was 6 recipient mice total).

**Flow cytometry.** Detailed methods for flow cytometry and all antibodies utilized are provided in the Supplemental Materials.

**Histology.** Detailed methods for histological analyses and antibodies used for immunohistochemistry are provided in the Supplemental Materials.

**Western blotting.** Detailed methods for Western blotting and all antibodies utilized are provided in the Supplemental Materials.

**Colony-forming assays and in vitro and in vivo drug studies.** Detailed methods for colony-forming assays and in vitro and in vivo drug studies are provided in the Supplemental Materials.

**Author contributions**

JT, Ay, SSC, CM, LB, DI, and YRC performed the experiments. DP, RB, EC, LAA, TIM, MA, and SA performed sequencing and sequencing analyses. EC, KM, KE, BBT, NK, and MS helped with drug experiments. BHD, MR, and JFH performed histology analysis. JM, ELD, DMH, and JHP treated the patient. JT, JHP, and OAW wrote the manuscript. All authors approved the manuscript.

**Acknowledgments**

JT is supported by grants from The Conquer Cancer Foundation of the American Society of Clinical Oncology, The American Association for Cancer Research, the American Society of Hematology, and the Robert Wood Johnson Foundation. JHP is supported by grants from the Conquer Cancer Foundation of the American Society of Clinical Oncology, the Leukemia and Lymphoma Society, the National Comprehensive Cancer Network, and the American Society of Hematology. OAW is supported by grants from the Edward P. Evans Foundation, the Department of Defense Bone Marrow Failure Research Program (BM150092 and W81XWH-12-1-0041), NIH/NHLBI (R01 HL128239, NIH/NCI (R01 CA201247-01A1), the Leukemia and Lymphoma Society, the Pershing Square Sohn Cancer Research Alliance, and a MSKCC core grant (P30 CA008748).

Address correspondence to: Omar Abdel-Wahab or Jae H. Park, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA. Phone: 646.888.3487; Email: abdelwao@mskcc.org (O. Abdel-Wahab). Phone: 212.639.4048; Email: parkj6@mskcc.org (J. Park).